Atty. Docket No: 05618.P4124X PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Eugene T. Michal, et al.

Application No.: 10/802,955

Filing Date: March 16, 2004

For: METHODS AND COMPOSITIONS TO TREAT MYOCARDIAL CONDITIONS

Examiner: Ford, Allison M.

Art Unit: 1651

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a copy of Information Disclosure Citation Form PTO-1449 or PTO/SB/08 together with copies of the documents cited on that form, except for copies not required to be submitted (e.g., copies of U.S. patents and U.S. published patent applications need not be enclosed). It is respectfully requested that the cited documents be considered and that the enclosed copy of Information Disclosure Citation Form PTO-1449 or PTO/SB/08 be initialed by the Examiner to indicate such consideration and a copy thereof returned to applicant(s).

Pursuant to 37 C.F.R. § 1.97, the submission of this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed as an admission that the information cited in this statement is material to patentability.

Pursuant to 37 C.F.R. § 1.97, this Information Disclosure Statement is being submitted under one of the following (as indicated by an "X" to the left of the appropriate paragraph):

X 37 C.F.R. §1.97(b).

_____ 37 C.F.R. §1.97(c). If so, then enclosed with this Information Disclosure Statement is one of the following:

____ A statement pursuant to 37 C.F.R. §1.97(e) or

____ A check for $_____ for the fee under 37 C.F.R. § 1.17(p).

_____ 37 C.F.R. §1.97(d). If so, then enclosed with this Information Disclosure Statement are the following:

(1) A statement pursuant to 37 C.F.R. §1.97(e); and

(2) A check for $_____ for the fee under 37 C.F.R. §1.17(p) for submission of the Information Disclosure Statement.

If there are any additional charges, please charge Deposit Account No. 02-2666.

Respectfully submitted,

BLAKELY, SOKOLOFF, TAYLOR & ZAFMAN LLP

Dated: 5/11, 2007

James C. Scheller, Jr.
Reg. No. 31,195

12400 Wilshire Blvd.
Seventh Floor
Los Angeles, CA 90025-1026
(408) 720-8300

FIRST CLASS CERTIFICATE OF MAILING (37 C.F.R. § 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on: May 11, 2007.

Date of Deposit

CONNIE THAYER

Name of Person Mailing Correspondence

Connie Thayer — 5-11-07

Signature — Date

Substitute for Form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(use as many sheets as necessary)*				Application Number	10/802,955
				Filing Date	March 16, 2004
				First Named Inventor:	Eugene T. Michal
				Art Unit	1651
				Examiner Name	Ford, Allison M.
Sheet	1	**of**	8	Attorney Docket No.	005618.P4124X

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
	1.	Allemann, E. et al. "Kinetics of Blood Component Adsorption on poly(D,L-lactic acid) Nanoparticles: Evidence of Complement C3 Component Involvement," J. Biomed. Mater Res. 37(2):229-234 (Nov. 1997), Abstract downloaded from the Internet at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed, 1 page.	
	2.	Assmus, B. et al. "Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI)," Circulation (2002), 106:3009-3017, first page only (1 page).	
	3.	Capan, Y. et al. "Preparation and Characterization of Poly(D,L-lactide-co-glycolide) Microspheres for Controlled Release of Human Growth Hormone," AAPS PharmSciTech. 2003; 4(2): article 28. Downloaded from the Internet at: http://www.aapspharmscitech.org/view.asp?art=pt040228&pdf=yes (12 pages).	
	4.	Caplan, M.J. et al. "Dependence on pH of Polarized Sorting of Secreted Proteins," Nature 329 (October 15, 1987), p. 630.	
	5.	Desai, M. et al. "Polymer bound EDC (P-EDC): A convenient reagent for formation of an amide bond," Tetrahedron Letters 34(48):7685-7688 (Nov 1993), Abstract downloaded from the Internet at: http://www.sciencedirect.com, 1 page.	
	6.	Etzion, Sharon et al. "Influence of Embryonic Cardiomyocyte Transplantation on the Progression of Heart Failure in a Rat Model of Extensive Myocardial Infarction," J. Mol. Cell Cardiol. 33:1321-1330 (May 2001).	
	7.	Ferrara, N. "Role of Vascular Endothelial Growth Factor in the Regulation of Angiogenesis," Kidney International 56(3):794-814 (1999), Abstract downloaded from the Internet at: http://www.nature.com/ki/journal/v56/n3/abs/4490967a.html, 1 page.	
	8.	Fuchs, S. et al. "Catheter-Based Autologous Bone Marrow Myocardial Injection in No-Option Patients with Advanced Coronary Artery Disease," J. Am. Coll. Cardiol. 41(10):1721-1724 (2003).	
	9.	Gref, R. et al. "Biodegradable Long-Circulating Polymeric Nanospheres," Science 263(5153):1600-1603 (Mar 1994), Abstract downloaded from the Internet at: http://www.sciencemag.org/cgi/content/abstract/263/5153/1600, 1 page.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for Form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(use as many sheets as necessary)*				Application Number	10/802,955
				Filing Date	March 16, 2004
				First Named Inventor:	Eugene T.. Michal
				Art Unit	1651
				Examiner Name	Ford, Allison M.
Sheet	2	**of**	8	Attorney Docket No.	005618.P4124X

	10.	Henry, R.R. et al. "Insulin Action and Glucose Metabolism in Nondiabetic Control and NIDDM Subjects. Comparison Using Human Skeletal Muscle Cell Cultures" Diabetes, 44(8):936-946 (1995), Abstract downloaded from the Internet at: http://diabetes.diabetesjournals.org/cgi/content/abstract/44/8/936, 1 page.	
	11.	Holland, N.B. et al. "Biomimetic Engineering of Non-Adhesive glycocalyx-like Surfaces Using Oligosaccharide Surfactant Polymers," Nature 392:799-801 (Apr 1998), Abstract downloaded from the Internet at: http://www.nature.com, 1 page.	
	12.	Hovinen, J. et al. "Synthesis of 3'-functionalized oligonucleotides on a single solid support," Tetrahedron Letters 34(50):8169-8172 (Dec 1993), Abstract downloaded from the Internet at: http://www.sciencedirect.com, 1 page.	
	13.	Huynh, T.V. et al. "Constructing and Screening cDNA Libraries in λgt10 and λgt11," Chapter 2, in DNA Cloning, Volume 1: A Practical Approach, ed. by D.M. Glover, pp. 49-78.	
	14.	Indik, Z.. et al. "Production of Recombinant Human Tropoelastin: Characterization and Demonstration of Immunologic and Chemotactic Activity," Arch. Biochem. Biophys. 280(1):80-86 (Jul 1990), Abstract downloaded from the Internet at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed, 1 page.	
	15.	Iskandrian, A.S. et al. "Nuclear Cardiac Imaging: Principles and Applications," second edition, F.A. Davis Co., Philadelphia (1996), cover page, title page and TOC (5 pages total).	
	16.	Isner, J.M. "Vascular Endothelial Growth Factor: Gene Therapy and Therapeutic Angiogenesis" Am. J. Cardiol. 1998 Nov 19; 82(10A): 63S-64S.	
	17.	Jonasson, P. et al. "Denatured states of human carbonic anhydrase II: an NMR study of hydrogen/deuterium exchange at tryptophan-indole-H_n sites," FEBS Letters 445 (1999), pp. 361-365.	
	18.	Kawasuji, M. et al. "Therapeutic Angiogenesis with Intramyocardial Administration of Basic Fibroblast Growth Factor," Ann Thorac Surg 69:1155-1161 (2000), Abstract downloaded from the Internet at: http://ats.ctsnetjournals.org/cgi/content/abstract/69/4/1155, 2 pages.	
	19.	Kinart et al. "Electrochemical Studies of 2-hydroxy-3-(3,4-dimethyl-9-oxo-9H-thioxanthen-2-yloxy)N,N,N-trimethyl-1-propanium chloride," J. Electroanal. Chem 294 (1990), pp. 293-297.	
	20.	Kipshidze, N. et al. "Therapeutic Angiogenesis for Critical Limb Ischemia to Limit or Avoid Amputation," The Journal of Invasive Cardiology 11(1):25-28, (January 1999).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for Form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(use as many sheets as necessary)*				Application Number	10/802,955
				Filing Date	March 16, 2004
				First Named Inventor:	Eugene T. Michal
				Art Unit	1651
				Examiner Name	Ford, Allison M.
Sheet	3	**of**	8	Attorney Docket No.	005618.P4124X

	21.	Klein, S. et al. "Fibroblast Growth Factors as Angiogenesis Factors: New Insights Into Their Mechanism of Action," in Regulation of Angiogenesis, I.D. Goldberg and E.M. Rosen (eds.), 1997; 79:159-192.	
	22.	Laboratory of Liposome Research. "Liposomes: General Properties," downloaded from the Internet on February 9, 2006 at: http://www.unizh.ch/onkwww/lipos.htm, 5 pages.	
	23.	Leor, J. et al. "Gene Transfer and Cell Transplant: An Experimental Approach to Repair a 'Broken Heart', Cardiovascular Research 35 (1997), pp. 431-441.	
	24.	Leroux, J.C. et al. "An Investigation on the Role of Plasma and Serum Opsonins on the Internalization of Biodegradable poly(D,L-lactic acid) Nanoparticles by Human Monocytes," Life Sci. 57(7):695-703 (1995), Abstract downloaded from the Internet at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed, 1 page.	
	25.	Lewin, Benjamin. "Repressor is Controlled by a Small Molecule Inducer", Genes VII, Oxford University Press, 7th ed., pp. 277-280, (2000).	
	26.	Li, W.W. et al. "Lessons to be Learned from Clinical Trials of Angiogenesis Modulators in Ischemic Diseases," Chapter 33, in Rubanyi, G. (ed). Angiogenesis in Health & Disease: Basic Mechanisms and Clinical Applications, Marcel Dekker, Inc. New York (2000).	
	27.	Li, Y.Y. et al. "Differential Expression of Tissue Inhibitors of Metalloproteinases in the Failing Human Heart," Circulation 98(17):1728-1734, (1998).	
	28.	Long, D.M.et al. "Self-Cleaving Catalytic RNA," FASEB Journal, 7:25-30, (1993).	
	29.	Lopez, J. J. et al. "Angiogenic Potential of Perivascularly Delivered aFGF in a Porcine Model of Chronic Myocardial Ischemia," Am. J. Physiol. 274 (*Heart Circ. Physiol.* 43):H930-H936, (1998).	
	30.	Lopez, J. J. et al. "VEGF Administration in Chronic Myocardial Ischemia in Pigs," Cardiovasc Res. 40(2):272-281 (1998), Abstract downloaded from the Internet at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed, 1 page.	
	31.	Lu, L. et al. "Biodegradable Polymer Scaffolds for Cartilage Tissue Engineering," in Clinical Orthopaedics and Related Research, Carl T. Brighton (ed.). No. 391S, pp. S251-270, (2001).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for Form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(use as many sheets as necessary)*				Application Number	10/802,955
				Filing Date	March 16, 2004
				First Named Inventor:	Eugene T. Michal
				Art Unit	1651
				Examiner Name	Ford, Allison M.
Sheet	4	**of**	8	Attorney Docket No.	005618.P4124X

	32.	Mansour, S. et al. "Disruption of the proto-oncogene *int-2* in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes," Nature, 336:348-352, (1988).	
	33.	Martin, S.L. et al. "Total Synthesis and Expression in *Escherichia Coli* of a Gene Encoding Human Tropoelastin," Gene (1995), Abstract, 1 page.	
	34.	McDevitt, T. et al. "*In vitro* Generation of Differentiated Cardiac Myofibers on Micropatterned Laminin Surfaces," J. Biomed Mater Res. 60:472-479, (2002).	
	35.	Narmoneva, D.A. et al. "Self-assembling short oligopeptides and the promotion of angiogenesis," Biomaterials 26 (2005) 4837-4846.	
	36.	Nguyen, Kytai T. et al. "Photopolymerizable Hydrogels for Tissue Engineering Applications," Biomaterials 23:4307-4314, (2002).	
	37.	Nikolic, S.D. et al. "New Angiogenic Implant Therapy Improves Function of the Ischemic Left Venticle," supplement to Circulation. Abstracts From Scientific Sessions 2000, 102(18):II-689, Abstract 3331 (Oct. 2000).	
	38.	Nitinol Technical Information, "NiTi Smart Sheets," downloaded from the Internet on December 10, 2002 at: http://www.sma-inc.com/information.html, 1 page.	
	39.	Ohyanagi, H. et al. "Kinetic Studies of Oxygen and Carbon Dioxide Transport into or from Perfluorochemical Particles," Proc. ISAO vol. 1 *(Artificial Organs vol. 2 (Suppl.))*, pp. 90-92 (1977).	
	40.	Ozbas, B. et al. "Salt-Triggered Peptide Folding and Consequent Self-Assembly into Hydrogels with Tunable Modulus," Macromolecules 37(19):7331-7337, (2004).	
	41.	Ozbas-Turan, Suna. "Controlled Release of Interleukin-2 from Chitosan Microspheres," Journal of Pharmaceutical Sciences 91(5):1245-1251, (May 2002).	
	42.	Palmiter R. et al. "Germ-Line Transformation of Mice," Ann. Rev. Genet. 20:465-499, (1986).	
	43.	Patrick, C.R. "Mixing and Solution Properties of Organofluorine Compounds," Chapter 10, in Preparation, Properties and Industrial Applications of Organofluorine Compounds," R.E. Banks (ed.), 1st edition, pp. 323-342, Ellis-Horwood Ltd., Chichester:England (1982).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(use as many sheets as necessary)*				Application Number	10/802,955
				Filing Date	March 16, 2004
				First Named Inventor:	Eugene T. Michal
				Art Unit	1651
				Examiner Name	Ford, Allison M.
Sheet	5	**of**	8	Attorney Docket No.	005618.P4124X

	44.	PCT Invitation to Pay Additional Fees for International Appln No. PCT/US03/18360, mailed 4 November 2003 (3 pgs).	
	45.	PCT International Search Report for International Appln No. PCT/US03/18360, mailed 28 January 2004 (7 pgs).	
	46.	PCT International Search Report for International Appln. No. PCT/US03/30464, mailed 9 February 2004 (5 pages).	
	47.	PCT International Preliminary Report on Patentability for International Appln. No. PCT/US2004/011356, mailed 3 November 2005 (6 pgs).	
	48.	PCT International Search Report and Written Opinion for International Appln No. PCT/US2005/045627, mailed 13 October 2006 (15 pgs).	
	49.	Peattie, R.A. et al. "Stimulation of In Vivo Angiogenesis by Cytokine-Loaded Hyaluronic Acid Hydrogel Implants," Biomaterials (June 2004) 25(14), Abstract downloaded from: www.sciencedirect.com, 2 pages.	
	50.	Penta, K. et al. "Dell Induces Integrin Signaling and Angiogenesis by Ligation of αVβ3," J. Biolog. Chem. 274(16):11101-11109, (April 1999).	
	51.	Perin, E.C. et al. "Transendocardial, Autologous Bone Marrow Cell Transplantation for Severe, Chronic, Ischemic Heart Failure," Circulation (2003), 1 page.	
	52.	Pouzet, B. et al. "Is Skeletal Myoblast Transplantation Clinically Relevant in the Era of Angiotensin-Converting Enzyme Inhibitors?" Circulation 104[suppl I]:I-223 - I-228, (Sep 2001).	
	53.	Prather et al. "Nuclear Transplantation in Early Pig Embryos," Biol. Reprod. 41:414-418, (1989).	
	54.	ProSci Incorporated, "ILPIP (CT) Peptide," 1 page.	
	55.	Quellec, P. et al. "Protein Encapsulation Within Polyethylene Glycol-coated Nanospheres. I. Physicochemical Characterization," J. Biomed. Mater. Res. 42(1), (1998) Abstract, 1 page.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for Form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(use as many sheets as necessary)*				Application Number	10/802,955
				Filing Date	March 16, 2004
				First Named Inventor:	Eugene T. Michal
				Art Unit	1651
				Examiner Name	Ford, Allison M.
Sheet	6	**of**	8	Attorney Docket No.	005618.P4124X

	56.	Ramirez-Solis, R. et al. "Gene Targeting in Embryonic Stem Cells," Methods in Enzymology, 225:855-878, (1993).	
	57.	Rowley, J. et al. "Alginate Hydrogels as Synthetic Extracellular Matrix Materials," Biomaterials 20:45-53, (1999).	
	58.	Sbaa-Ketata, E. et al. "Hyaluronan-Derived Oligosaccharides Enhance SDF-1-Dependent Chemotactic Effect on Peripheral Blood Hematopoietic $CD34^+$ Cells," Stem Cells (2002), 20(6):585-587, "Letter to the Editor" downloaded from the Internet at: http://stemcells.alphamedpress.org/cgi/content/full/20/6/585, 5 pages.	
	59.	Segura, T. et al. "[216c]-DNA Delivery From Hyaluronic Acid/Collagen Hydrogels," AIchE Technical Program Paper Detail, American Institute of Chemical Engineers (ALCHE Annual Meeting 2003), Abstract downloaded from the Internet at: http://www.aiche.org/cofnerences/techprogram/paperdetail.asp?PaperID=1465&DSN=annual, 2 pages.	
	60.	Segura, T. et al. "Crosslinked Hyaluronic Acid Hydrogels: A Strategy to Functionalize and Pattern," Biomaterials 26:359-371, (2005).	
	61.	Segura, T. et al. "Substrate-Mediated DNA Delivery: Role of the Cationic Polymer Structure and Extent of Modification," Journal of Controlled Release 93:69-84, (2003).	
	62.	Segura, T. et al. "Surface-Tethered DNA Complexes for Enhanced Gene Delivery," Bioconjugate Chem 13(3):621-629, (2002).	
	63.	Shibasaki, F. et al. "Suppression of Signalling Through Transcription Factor NF-AT by Interactions Between Calcineurin and Bcl-2," Nature (1997) 386(6626), Abstract downloaded from the Internet at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Text&DB=pubmed, 1 page.	
	64.	Shin, H. et al. "In Vivo Bone & Soft Tissue Response to Injectable, Biodegradable oligo(poly(ethylene glycol) fumerate) Hydrogels," Biomaterials 24:3201-3211, (March 2003).	
	65.	Shu, et al. "Disulfide-crosslinked hyaluronan-gelatin hydrogel films: a covalent mimic of the extracellular matrix for in vitro cell growth," Biomaterials (Sep 2003) 24(21), Abstract downloaded from the Internet at: http://www.sciencedirect.com, 1 page.	
	66.	Simons, M. et al. "Clinical Trials in Coronary Angiogenesis: Issues, Problems, Consensus - An Expert Panel Summary," Circulation 102:e73-e86, (Sep 2000), pp. 1-14.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/802,955
				Filing Date	March 16, 2004
				First Named Inventor:	Eugene T. Michal
				Art Unit	1651
				Examiner Name	Ford, Allison M.
Sheet	7	of	8	Attorney Docket No.	005618.P4124X

	67.	Spenlehauer, G. et al. "In vitro and in vivo Degradation of poly (D,L lactide/glycolide) Type Microspheres Made by Solvent Evaporation Method," Biomaterials 10:557-563, (Oct 1989).	
	68.	Spinale, Francis G. "Matrix Metalloproteinases - Regulation and Dysregulation in the Failing Heart," Circ. Res. 90:520-530, (2002).	
	69.	Springer, M. et al. "Angiogenesis Monitored by Perfusion with a Space-Filling Microbead Suspension," Mol. Ther. (2000) 1(1):82-87, Abstract downloaded from the Internet at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed, 1 page.	
	70.	Storm, G. et al. "Surface Modification of Nanoparticles to Oppose Uptake by the Mononuclear Phagocyte System," Advanced Drug Delivery Reviews (Oct 1995), 17(1):31-48, Abstract downloaded from the Internet at: http://www.sciencedirect.com, 1 page.	
	71.	Strauer, B. et al. "Repair of Infarcted Myocardium by Autologous Intracoronary Mononuclear Bone Marrow Cell Transplantation in Humans," Circulation 106:1913-1918, (2002).	
	72.	Tybulewicz, V. et al. "Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-*abl* proto-oncogene," Cell (June 1991), 65(7):1153-1163, Abstract downloaded from the Internet at: http://www.sciencedirect.com, 2 pages.	
	73.	Unger, E.F. et al. "Effects of a Single Intracoronary Injection of Basic Fibroblast Growth Factor in Stable angina Pectoris" Am. J. Cardiol 85(12):1414-1419 (June 2000), Abstract downloaded from the Internet at: http://www.sciencedirect.com, 2 pages.	
	74.	van der Giessen, W.J. et al. "Marked Inflammatory Sequelae to Implantation of Biodegradable and Nonbiodegradable Polymers in Porcine Coronary Arteries," Circulation 94(7):1690-1697 (Oct 1996).	
	75.	van Luyn, M.J.A. et al. "Cardiac Tissue Engineering: Characteristics of In Unison Contracting Two- and Three-Dimensional Neonatal Rat Ventricle Cell (Co)-Cultures," Biomaterials 23:4793-4801, (2002).	
	76.	Vercruysse, K.P. et al. "Synthesis and in Vitro Degradation of New Polyvalent Hydrazide Cross-Linked Hydrogels of Hyaluronic Acid," Bioconjugate Chem 8(5):686-694 (1997), Abstract downloaded from the Internet at: http://pubs.acs.org/cgi-bin/abstract.cgi/bcches/1997/8/i05/abs/bc9701095.html, 1 page.	
	77.	Visscher, G.E. et al. "Tissue Response to Biodegradable Injectable Microcapsules," Journal of Biomaterials Applications 2 (July 1987), pp. 118-119.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for Form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/802,955
				Filing Date	March 16, 2004
				First Named Inventor:	Eugene T. Michal
				Art Unit	1651
				Examiner Name	Ford, Allison M.
Sheet	8	of	8	Attorney Docket No.	005618.P4124X

	78.	Vlodavsky, I. et al. "Extracellular Matrix-resident Basic Fibroblast Growth Factor: Implication for the Control of Angiogenesis," J. Cell Biochem, 45(2):167-176 (Feb 1991), Abstract downloaded from the Internet at: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed, 1 page.	
	79.	Wasielewski, S. "Ischämische Erkrankungen, Gefäbneubildung anregen" Deutsche Apotheker Zeitung (January 2000), 140(3):232-233, Stuttgart (DE).	
	80.	Witzenbichler, B., et al. "Vascular Endothelial Growth Factor-C (VEGF-C/VEGF-2) Promotes Angiogenesis in the Setting of Tissue Ischemia" AM Pathol. 153(2):381-394, (Aug 1998).	
	81.	Zervas, L. et al. "On Cysteine and Cystine Peptides. II. S-Acylcysteines in Peptide Synthesis," J. Am. Chem. Soc. 85(9):1337-1341, (May 1963).	
	82.	Zheng, W. et al. "Mechanisms of coronary angiogenesis in response to stretch: role of VEGF and TGF-beta," Am J Physiol Heart Circ Physiol. 280(2):H909-H917, (February 2001).	
	83.	Zimmermann, W. et al. "Engineered Heart Tissue for Regeneration of Diseased Hearts," Biomaterials 25:1639-1647, (2004).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.